PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
Condition: Breast Neoplasm Interventions: Drug: AZD6738; Drug: Olaparib; Drug: Durvalumab Sponsors: Institute of Cancer Research, United Kingdom; AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Research | Study